Conavi Medical Enters into Funding Agreements for Over $20 Million to Support Commercialization of its Innovative Intravascular Image Guidance Technology

Conavi Medical Inc., a leader of hybrid imaging guidance for common minimally invasive heart procedures, has entered into agreements for over $20 million in funding to support commercialization and growth as it prepares its innovative Novasight Hybrid® System for market. The company aims to raise an additional $10 million as part of an ongoing financing effort.

Novasight Hybrid System is the first and only clinical system that enables simultaneous and co-registered imaging of coronary arteries with both intravascular ultrasound (IVUS) and optical coherence tomography (OCT).

The Novasight Hybrid System was recently featured as part of a live case performed by New York Presbyterian Hospital and broadcast during the TCT 2021 conference, the world’s premier meeting for interventional cardiovascular medicine.

Conavi is an OBIO® member and participated in previous OBIO Investment Summits.